Lewy Body Dementia Market Report 2026

Lewy Body Dementia Market Overview

• Lewy Body Dementia market size has reached to $1.2 billion in 2025 • Expected to grow to $1.69 billion in 2030 at a compound annual growth rate (CAGR) of 6.9% • Growth Driver: Rising Prevalence Of Brain-Related Disorders Driving The Market Growth • Market Trend: Research Investments Driving Advancements In Lewy Body Dementia Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Lewy Body Dementia Market?

Lewy body dementia (LBD) is a neurodegenerative condition caused by abnormal protein deposits in the brain, impacting cognition, movement, and behavior. This results in a gradual decline in both mental and physical abilities, with symptoms including memory loss, hallucinations, tremors, and motor difficulties. Effective management is essential to address the cognitive and physical challenges associated with the disorder. The main diagnosis types of lewy body dementia are clinical diagnosis and biomarker-based diagnosis. Clinical diagnosis involves identifying diseases like Lewy body dementia based on medical history, symptoms, and physical exams, aiding early recognition and treatment. It is treated with various medications, such as cholinesterase inhibitors, antipsychotics, antidepressants, and others, and used by various end-users, including hospitals, specialty clinics, long-term care facilities, and others.

What Is The Lewy Body Dementia Market Growth Forecast?

The lewy body dementia market size is expected to see strong growth in the next few years. It will grow to $1.69 billion in 2030 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to improving diagnostic accuracy, rising burden of chronic neurological diseases, expanding specialty clinic networks, increased caregiver and patient support programs, higher healthcare spending on dementia care. Major trends in the forecast period include rising prevalence of neurodegenerative disorders, increasing awareness and early recognition of lbd, growing demand for accurate differential diagnosis, expansion of symptom-specific drug utilization, rising need for long-term care and disease management.

Global Lewy Body Dementia Market Segmentation

1) By Diagnosis: Clinical Diagnosis, Biomarker-Based Diagnosis 2) By Medication: Cholinesterase Inhibitors, Antipsychotics, Antidepressants, Other Medications 3) By End-User: Hospitals, Specialty Clinics, Long-Term Care Facilities, Other End-Users Subsegments: 1) By Clinical Diagnosis: Neuropsychological Testing, Neurological Examination, Medical History Review, Cognitive Function Assessment 2) By Biomarker-Based Diagnosis: Cerebrospinal Fluid (CSF) Biomarkers, Imaging Biomarkers (PET, MRI)

What Is The Driver Of The Lewy Body Dementia Market?

The rise in the prevalence of brain-related disorders is expected to propel the growth of the lewy body dementia market going forward. Brain-related disorders refer to a range of conditions affecting the brain’s structure and function, leading to cognitive decline, memory loss, and behavioral changes. The prevalence of brain-related disorders is increasing due to factors such as aging, genetic predisposition, and environmental influences. The increasing prevalence of brain-related disorders boosts the demand for better treatments and early detection for lewy body dementia, which in turn drives research, funding, and innovation, leading to faster advancements in diagnosis and therapy for LBD. For instance, in October 2023, according to the World Federation of Neurology, the UK-based association of national neurological societies, more than 40% of the global population is affected by neurological conditions, with this burden expected to almost double by 2050. Therefore, the rise in the prevalence of brain-related disorders will drive the growth of the lewy body dementia industry.

Key Players In The Global Lewy Body Dementia Market

Major companies operating in the lewy body dementia market are Eli Lilly and Company, Mayo Foundation for Medical Education and Research, Eisai Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Georgetown University Medical Center, Alzheimer's Society, BioArctic AB, Annovis Bio Inc., Sun Pharma Advanced Research Company Limited, Voyager Therapeutics Inc., Cognition Therapeutics, Athira Pharma, Allergan plc, Inhibikase Therapeutics, CuraSen Therapeutics Inc., CervoMed Inc., AC Immune SA, ProMIS Neurosciences Inc., Aptinyx Inc., EIP Pharma Inc.

Global Lewy Body Dementia Market Trends and Insights

Major companies operating in the lewy body dementia market are focusing on research investment to develop more effective neurodegenerative treatments. Research investment involves dedicating financial resources, time, and effort to scientific and technological studies aimed at uncovering new insights, developing innovative solutions, or enhancing current practices. It supports the exploration of diseases and the creation of new medications, all with the ultimate goal of improving patient outcomes. For instance, in March 2023, the National Institute on Aging, a US-based government agency, awarded $21 million to support drug development research for Lewy Body Dementia (LBD). Researchers at the University of Miami Miller School of Medicine are initiating a Phase 2b study of neflamapimod following encouraging early results.

What Are Latest Mergers And Acquisitions In The Lewy Body Dementia Market?

In March 2023, CND Life Sciences, a US-based developer of highly accurate skin-based tests to help clinicians diagnose dementia with Lewy bodies, partnered with Beth Israel Deaconess Medical Center (BIDMC) to enhance its skin-based diagnostic tool for neurodegenerative diseases. This partnership aims to leverage advanced technology to improve the detection of misfolded alpha-synuclein proteins and explore additional protein markers associated with other neurodegenerative disorders, ultimately facilitating more accurate diagnoses and better patient outcomes as new therapies emerge. Beth Israel Deaconess Medical Center (BIDMC) is a US-based company specializing in diagnosing and treating conditions such as Lewy body disease.

Regional Outlook

North America was the largest region in the lewy body dementia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Lewy Body Dementia Market?

The lewy body dementia market consists of revenues earned by entities by providing services such as cognitive and motor function therapies, pharmaceutical treatments, and physical therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The lewy body dementia market also includes sales of sleep aids, mood stabilizers, and anxiolytics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Lewy Body Dementia Market Report 2026?

The lewy body dementia market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the lewy body dementia industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.